Core Viewpoint - The company, Weigao Blood Purification Products Co., Ltd., has shown stable financial performance with a slight increase in revenue and net profit, while also experiencing changes in shareholder structure and trading activity. Group 1: Financial Performance - For the period from January to September 2025, the company achieved an operating income of 2.736 billion yuan, representing a year-on-year growth of 3.45% [2] - The net profit attributable to shareholders for the same period was 341 million yuan, reflecting a year-on-year increase of 7.92% [2] - Cumulative cash dividends since the company's A-share listing amount to 65.8213 million yuan [2] Group 2: Shareholder and Trading Activity - As of September 30, the number of shareholders decreased to 24,800, a reduction of 20.95% compared to the previous period [2] - The average number of circulating shares per shareholder increased by 26.51% to 1,535 shares [2] - On December 18, the company recorded a financing buy-in amount of 12.4342 million yuan, with a net financing buy of 1.7140 million yuan [1]
威高血净12月18日获融资买入1243.42万元，融资余额1.40亿元